Fluorescence of Ocular Surface in a Covid -19 Patient After Favipiravir Treatment: a Case Report

Abstract

BackgroundFavipiravir is used in treatment of Covid-19 patients. We aimed in this case report to share of ocular surface fluorescence in a patient after Favipiravir treatment.Case PresentationA 20 years-old male ,with no medical history, applied to us with blurry vision and blue light reflection after Covid-19 treatment with Favipiravir. We observed bilateral fluorescence on his eyes and fluorescence of his nails. Biomicroscopic examination was insignificant.Conclusion We investigated the fluorescence of favipiravir tablets under ultraviolet light. Drug demonstrated fluorescence. We recorded the favipiravir fluorescence independently of the patient. This is strong evidence that the fluorescence of the patient’s ocular surface and favipiravir are linked.

Nail and hair findings developing in patients treated for COVID‐19 infection fluorescence of keratinized tissues on Wood’s lamp in COVID‐19 disease

“…17 The UV light source used in this report had 365-395 nm wavelength, while Wood's lamp has a wavelength between 320 and 400 nm. 20 Therefore, we also examined the favipravir tablet under Wood's lamp and, similar to that of Doran et al, 19 we detected fluorescence in the fragmented and dissolved forms, while fluorescence was not observed in the whole tablet.…”

“…Hyperuricemia, QTc prolongation and teratogenity are associated with the use of this agent, and short‐term use is advocated. Doran et al 19 reported ocular surface fluorescence in their patient following favipravir treatment for COVID‐19. The patient had visual impairment which started with the initiation of favipravir therapy and resolved after cessation of it.…”